Safety Assessment of an Anti-Obesity Drug (Sibutramine)A Retrospective Cohort Study

被引：0
|
作者：
Jerzy E. Tyczynski
Denise M. Oleske
David Klingman
Cheryl P. Ferrufino
Won Chan Lee
机构：
[1] Product Safety and Pharmacovigilance,Astellas Pharma Global Development, Inc.
[2] Global Surveillance and Pharmacoepidemiology,Abbott Laboratories
[3] Dept R4ED,Health Economics and Outcomes Research
[4] IMS Health Inc.,undefined
来源：
Drug Safety | 2012年 / 35卷 / 8期
关键词：
Acute Myocardial Infarction; Orlistat; Rimonabant; Sibutramine; Label Status;
D O I：
10.1007/BF03261960
中图分类号：
学科分类号：
摘要：
Background: Obesity is a serious and rapidly growing health problem worldwide. Few therapies are available beyond diet, exercise and bariatric surgery. A previously approved medication, sibutramine, has been withdrawn from the market due to concerns over the potential of increased risk of cardiovascular (CV) events, based on a phase IV clinical trial that included only individuals at high risk for CV events.
引用
收藏
页码：629 / 644
页数：15
相关论文
共 50 条
  • [41] Orlistat: its current status as an anti-obesity drug
    Ballinger, A
    Peikin, SR
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 440 (2-3) : 109 - 117
  • [42] DRUG UTILISATION STUDY OF ANTI-OBESITY PRODUCTS DISPENSED BY PHARMACIES IN SOUTH AFRICA
    Truter, I
    VALUE IN HEALTH, 2017, 20 (09) : A546 - A547
  • [43] Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine
    Heal, DJ
    Aspley, S
    Prow, MR
    Jackson, HC
    Martin, KF
    Cheetham, SC
    INTERNATIONAL JOURNAL OF OBESITY, 1998, 22 : S18 - S28
  • [44] The anti-obesity drug orlistat reveals anti-viral activity
    Ammer, Elisabeth
    Nietzsche, Sandor
    Rien, Christian
    Kuehnl, Alexander
    Mader, Theresa
    Heller, Regine
    Sauerbrei, Andreas
    Henke, Andreas
    MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2015, 204 (06) : 635 - 645
  • [45] The anti-obesity drug orlistat reveals anti-viral activity
    Elisabeth Ammer
    Sandor Nietzsche
    Christian Rien
    Alexander Kühnl
    Theresa Mader
    Regine Heller
    Andreas Sauerbrei
    Andreas Henke
    Medical Microbiology and Immunology, 2015, 204 : 635 - 645
  • [46] Mechanism of the thermogenic effect of Metabolite 2 (BTS 54 505), a major pharmacologically active metabolite of the novel anti-obesity drug, sibutramine
    Liu, YL
    Heal, DJ
    Stock, MJ
    INTERNATIONAL JOURNAL OF OBESITY, 2002, 26 (09) : 1245 - 1253
  • [47] Mechanism of the thermogenic effect of Metabolite 2 (BTS 54 505), a major pharmacologically active metabolite of the novel anti-obesity drug, sibutramine
    Y-L Liu
    DJ Heal
    MJ Stock
    International Journal of Obesity, 2002, 26 : 1245 - 1253
  • [48] A risk-benefit assessment of anti-obesity drugs
    Kolanowski, J
    DRUG SAFETY, 1999, 20 (02) : 119 - 131
  • [49] A Risk-Benefit Assessment of Anti-Obesity Drugs
    Jaroslaw Kolanowski
    Drug Safety, 1999, 20 : 119 - 131
  • [50] Challenges in the assessment of reproductive toxicology of anti-obesity drugs
    Bolze, F.
    Rojas, J. M.
    Bhuwania, R.
    Egecioglu, N. E.
    Dalgaard, M.
    Andersen, L. W.
    TOXICOLOGY LETTERS, 2018, 295 : S30 - S30
12345